$1.68B in CY2024 Part D spend332K claims · 61K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Apremilast used for?
OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis ( 1.1 ) Plaque psoriasis who are candidates for phot....
Is there a generic for Apremilast?
Yes. 15 ANDAs filed at FDA, 5 generic manufacturers currently shipping.
How much does my plan pay for Apremilast?
Across 329 Part D plans, Apremilast averages $93.18/unit (NADAC). Lowest available: $89.95/unit. Highest in distribution: $98.89/unit.
Is Apremilast on the FDA shortage list?
No. Apremilast is not currently on the FDA Drug Shortage Database.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.